What we offer
No matter whether you need a protein binder for a therapeutic use, your daily assays, your cutting-edge diagnostic, or for blocking or binding specific protein epitopes - AffinityAI can provide.
We offer rapid and custom solutions to serve all your needs and will align with you at each stage to ensure we deliver the high quality product you deserve.
What are de novo designed protein binders?
​
De novo designed protein binders are fully synthetic proteins engineered to bind specifically to selected epitopes on target proteins. Their deliberate design gives them unique and superior characteristics compared to proteins derived from traditional in vivo or in vitro screening platforms.
​
High affinity
Our protein binders are AI-crafted to bind specifically to your target of interest with Kd's in the pM-nM range.
Known Epitope
We always know where our protein designs bind their target.
Fast development
From concept to in vitro validated binding in 6-10 weeks.
Customisable
We can design for a desired epitope, specificity, PTM, confirmational state, etc.
Defined target epitope
Unlike conventional antibodies, where the target epitope is determined by natural selection and challenging to identify, our AI de novo designed protein binders have predefined epitope-paratope interactions. Our AI protein design platform allows us to tailor the binding site to match the intended application.
Development
AI de novo designed protein binders are rapidly developed without animals or cell-based systems, making them efficient, ethical, and eco-friendly. AI designed nanobodies or de novo miniprotein scaffolds can be mass-produced in microbial systems for high yields at low cost.
Tags and incorporated functionalities
AI de novo designed proteins can be easily modified with functional tags for e.g. detection or linking to other proteins.
​
Ease of development
Discovery based antibody development can be difficult when targets are non-immunogenic or the antigen is hard to come by. AI de novo design overcomes these challenges, requiring only the target’s amino acid sequence for computational design and small quantities of the target for in vitro validation.
